Fast Five Quiz: Non-Hodgkin's Lymphoma: Mantle Cell Lymphoma Practice Essentials

Ann S. LaCasce, MD, MMSc


May 22, 2023

TP53 mutation is a well-established prognostic biomarker associated with poor prognosis and an inferior response to standard front-line therapies. In addition, risk stratification models have been established, including Ki67 index, age, lactate dehydrogenase levels, performance status, and white blood cell count.

Further, blastoid morphology as well as time to progression after front-line therapy indicate aggressive disease.

Learn more about MCL.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.